Sandoz Pushes Product Launch Plans As Novartis Shareholders Approve The Spin-Off
Portfolio Pulse from Vandana Singh
Novartis AG's shareholders have approved the 100% spin-off of Sandoz, planned for October 4, 2023. Sandoz plans to introduce at least five additional biologic drugs to enhance its attractiveness to investors. The company aims to bring five biosimilars to market within the next two years. Sandoz is the world's second-largest biosimilar manufacturer, behind Pfizer Inc. The company's adjusted core profit margins for 2023 are expected to be 18%-19%, down from 21.3% in 2022, but aims to rebound to 24%-26% by 2028.
September 15, 2023 | 10:54 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Novartis shareholders have approved the spin-off of Sandoz, which could potentially impact the company's stock.
The approval of the spin-off could potentially impact Novartis' stock as it could change the company's structure and operations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEUTRAL IMPACT
Sandoz is the world's second-largest biosimilar manufacturer, behind Pfizer Inc.
The news about Sandoz's plans could potentially impact Pfizer as it could affect the competition in the biosimilar market.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50
NEGATIVE IMPACT
Sandoz announced plans to launch a generic version of Johnson & Johnson's anti-inflammatory drug, Stelara.
The introduction of a generic version of Stelara by Sandoz could potentially impact Johnson & Johnson's revenues from the drug.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 70